Therapeutic targeting of the tumor vasculature

Gillian M Tozer1, Roy Bicknell

  • 1Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital Middlesex, United Kingdom.

Insights

Targeting tumor vasculature is key for cancer treatment. This review covers antiangiogenic and antivascular therapies, their combination with radiotherapy, and methods for developing new vascular-targeted strategies.

Area of Science:

  • Oncology
  • Vascular Biology
  • Cancer Therapeutics

Background:

  • Tumor vasculature is crucial for tumor growth and metastasis.
  • Targeting tumor blood vessels offers a promising therapeutic strategy.
  • Current research focuses on antiangiogenic and antivascular approaches.

Purpose of the Study:

  • To review current antiangiogenic and antivascular cancer therapies.
  • To explore the potential of combining these therapies with radiotherapy.
  • To discuss methods for identifying new vascular targets and evaluating novel strategies.

Main Methods:

  • Literature review of antiangiogenic and antivascular therapies.
  • Analysis of combination strategies with radiotherapy.
  • Examination of methods for target identification and in vivo model evaluation.

Main Results:

  • The review synthesizes current knowledge on vascular-targeted cancer therapies.
  • It highlights the potential benefits and challenges of combining therapies.
  • It outlines approaches for discovering and validating new therapeutic targets.

Conclusions:

  • Targeting tumor vasculature is a vital strategy in cancer therapy.
  • Combination therapies, including with radiotherapy, show promise.
  • Further research into novel targets and evaluation methods is essential.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...